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Abstract
Background: The malignant cells of cutaneous T cell lymphoma (CTCL) display immunogenic
peptides derived from the clonal T cell receptor (TCR) providing an attractive model for
refinement of anti-tumor immunization methodology. To produce a clinically meaningful anti-tumor
response, induction of cytotoxic anti-CTCL cells must be maximized while suppressive T
regulatory cells (Treg) should be minimized. We have demonstrated that engulfment of apoptotic
CTCL cells by dendritic cells (DC) can lead to either CD8 anti-CTCL responses or
immunosuppressive Treg induction. Treg generation is favored when the number of apoptotic cells
available for ingestion is high.
Methods: In this study, we sought to determine whether the balance between immunity and
immunosuppression could be shifted towards a CD8 anti-CTCL response by lowering the ratio of
apoptotic CTCL cells available for DC ingestion. CTCL cell apoptosis was produced by engagement
of the TCR by anti-CD3 antibody affixed to magnetic beads.
Results: The physical perturbation inherent in passage through a separation column induced
monocytes to differentiate into DC, demonstrated by increased expression of class II and CD86
and decreased expression of the monocyte marker CD14. The immature DC internalized and
processed apoptotic CTCL cells and could potentially present the tumor-derived peptides in the
context of MHC class I and II. As the number of apoptotic cells increased, there was a dose-
dependent increase in the expression of Treg markers CTLA-4, CD25, and FoxP3, with a ratio of
apoptotic cell/DC loading of > 10:1 corresponding to the greatest Treg induction. These inducible
phenotypic Treg also functionally inhibited CD8-mediated perforin expression in vitro. At lower
levels of apoptotic cell/DC loading of < 5:1, there was an expansion of the CD8 T cell compartment
with increased perforin expression and increased CTCL cell death, indicating anti-tumor activity.
Conclusion: These findings demonstrate that the ratio of apoptotic cells supplied to DC is an
important determinant of whether CD8 anti-tumor immunity or immunosuppression is generated.
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Background
Cutaneous T cell lymphoma (CTCL) is an umbrella desig-
nation that unifies a diverse group of clinical presenta-
tions on the basis of histopathologic and immunologic
criteria. The malignancy is a clonal proliferation of epider-
motropic T cells [1-3], that uniformly carry a common T
cell receptor (TCR) and also display cell surface expression
of a memory (CD45RO+), inducer (CD4+), and cutaneous
homing leukocyte antigen (CLA+) phenotype. Initially the
tumor cells localize in the skin of afflicted patients, sur-
rounding Langerhans cells that contribute to the CTCL
cell growth [4]. As the disease progresses, the malignant
cells become more poorly differentiated and often spread
hematogenously throughout the body, as a leukemia fore-
casting a much poorer prognosis. It is the early epidermal
focus of malignant T cells surrounding a central Langer-
hans cell [5], an immature member of the dendritic cell
(DC) series [6], that is the diagnostic hallmark of the dis-
ease, the Pautrier microabscess [2]. CTCL tumor cells lack
the co-stimulatory molecules required to trigger an
immune response contributing to their ability to evade
induction of anti-tumor immunity and thus, persist and
disseminate. Despite the role of DC in providing prolifer-
ative support for the malignancy, DC immunotherapy has
demonstrated clinical benefit in this disease [7,8].
We have recently found that passage of cells from CTCL
patients through an anti-CD3 magnetic bead column can
achieve the simultaneous induction of apoptosis in the
malignant T cell population and differentiation in the
monocyte population creating, after overnight culture, a
population of tumor-loaded DC capable of initiating an
immune response in vitro [9]. This column-based method
of generating tumor-loaded DC utilizes the mechanistic
principles discovered in extracorporeal photopheresis
(ECP), the first FDA-approved immunotherapy for cancer
[10]. Clinical trials of ECP have shown response rates of
73% in late stage CTCL patients with an extremely safe
side effect profile [11]. ECP has been recently modified by
the addition of an overnight incubation step. The new
procedure has been termed " Transimmunization",
wherein malignant T cells were rendered apoptotic by
ultraviolet A (UVA) light photo-activated 8-methoxypsor-
alen (8-MOP) and were avidly engulfed by immature DC,
whose transition from monocytes was triggered by the
physical perturbation produced when the cells were
passed through the UVA exposure plate of the ECP appa-
ratus. In Transimmunization, the transitioning DC and
the apoptosing leukocytes are co-cultivated overnight to
permit engulfment of the apoptotic cells and subsequent
processing and presentation of the tumor-derived pep-
tides prior to re-infusion into the host [12].
We have previously shown that when CTCL cells encoun-
ter autologous DC loaded with high numbers of apoptotic
cells, they adopt the phenotype and function of T regula-
tory (Treg) cells, expressing high levels of the Treg markers
CTLA-4, CD25, and FoxP3, as well as secreting inter-
leukin-10 (IL-10) and transforming growth factor-β (TBF-
β) and suppressing normal T cell antigen driven secretion
of interleukin-2 (IL-2) and interferon-γ(IFN-γ) [4]. The
induction of Treg from responding CTCL cells may be hin-
dering the effectiveness of existing immunotherapies for
CTCL, and understanding the mechanism of their induc-
tion is paramount to the generation of more effective
immunotherapy.
In these experiments, we sought to determine if the level
of apoptotic cell loading controlled the balance between
the development of an anti-tumor immune response and
immunosuppressive Treg cell generation. We found that
when lower numbers of apoptotic cells were processed by
DC, a CD8 T cell response could be stimulated while at
higher levels of apoptotic cell up-take by DC we could
induce CTCL cell Treg conversion and inhibit the CD8 T
cell response.
Methods
Patient Population
Specimens were obtained from a leukapheresis harvest of
CTCL patients (in accordance with the guidelines of the
Yale human investigation committee) undergoing treat-
ment with standard ECP. All patients had advanced dis-
ease with clonal CD4+ T cell populations present in the
peripheral circulation as determined by immunopheno-
typing with antibodies to the clonotypic variable region of
family-specific TCR or polymerase chain reaction to detect
rearrangements of the beta or gamma chain of the TCR as
well as CD8 T cell compartments > 10% of the circulating
lymphocyte population.
Cell Isolation
On Day 0, peripheral blood mononuclear cells (MNL)
were isolated from the leukapheresis harvest by centrifu-
gation over a ficoll-hypaque gradient followed by two
washes in RPMI 1640 (Gibco, Gaithersburg, MD) contain-
ing 10% AB serum and 2 mM EDTA. An aliquot of the
MNL was then isolated, purified, and cultured for subse-
quent re-addition on Day 1. Within this aliquot, CD4+
and CD8+ cells were column-purified using 40 μl Macs α-
human CD4 and CD8 microBeads (Miltenyi Bioteck,
Auburn CA) according to manufacturer's instructions. The
enriched CD4+ and CD8+ T cells (> 97% ± 0.5% CD4+ and
> 98% ± 0.5% CD8+, respectively) were suspended in
RPMI 1640 with 15% autologous serum and IL-2/IL-7 and
cultured individually in separate wells of a 12 well tissue
culture plate (Falcon). Another aliquot of the Day 0 iso-
lated MNL was reserved to construct the apoptotic cell and
DC dose response curves, and controls. MNL (2 × 107)
from the leukapheresis harvest were incubated with 40 μlJournal of Immune Based Therapies and Vaccines 2007, 5:2 http://www.jibtherapies.com/content/5/1/2
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Macs α-human CD3 microBeads following the manufac-
turer's directions. As previously described [9], CTCL cell
binding to CD3 antibody rendered the malignant T cells
apoptotic. As a control, another portion of MNL (2 × 107)
was incubated with 40 μl Macs α-human CD4
microBeads. Following the twenty minute incubation, the
cells were passed through the magnetic bead column,
allowing separation of the MNL into either CD3+ and
CD3- fraction or CD4+ and CD4- fractions. The CD3-
treated and CD4-treated cells were then cultured in 3 ml
RPMI 1640 containing 15% AB serum. In some experi-
ments, increasing doses of CD3-treated cells were added
to 105 autologous DC obtained from the column eluate to
create the dose response curves. Controls consisted of
increasing doses of CD4-treated CTCL cells added to 105
autologous DC.
On Day 1, the individually cultured column-purified CD4
and CD8 cells (106) were added to the CD3-treated apop-
totic cell-loaded DC as well as the CD4-treated control
population. After a second overnight culture, the cells
were harvested, counted, and immunophenotyped for
markers of T cells, DC, Tregs, and apoptotic cells.
Immunophenotyping
In order to monitor enrichment of the purified CD4+ and
CD8+ cell populations and to measure the effect of load-
ing DC with differing number of apoptotic malignant T
cells, the cells were stained by two-color immunofluores-
cence with a panel of antibodies to monocytes, DC, Tregs,
and cytotoxic T cells. Cells (1 × 106) were incubated with
10–20 μl of fluorochrome conjugated monoclonal anti-
body for 30 minutes in the dark at 4°C. The antibodies
were directly conjugated to fluorescein (FITC) or phyco-
erythrin (PE) and included: CD3-FITC (pan T cell); CD4-
FITC (inducer T cell); CD8-FITC (cytotoxic T cell); CD25-
FITC (IL2 receptor); CD14-FITC (monocytes); HLA-DR-
FITC (anti-class II MHC molecule) and CD86-PE (B7.2
co-stimulatory molecule) and their isotype controls. Cells
were washed once and suspended in PBS and read on a
FC500 flow cytometer (Beckman Coulter) within 24
hours.
Combined membrane and cytoplasmic staining was per-
formed following manufacturers instructions for cell fixa-
tion and permeabilization (Intraprep kit, Beckman
Coulter). Antibody combinations included: membrane
CD4-FITC/cytoplasmic CTLA4-PE (inhibitory member of
the co-stimulatory family); membrane CD3-FITC/cyto-
plasmic CTLA4-PE; membrane CD4-FITC/cytoplasmic
FoxP3 (inhibitory transcription factor); membrane CD3-
FITC/cytoplasmic Apo2.7-PE (apoptotic cells); membrane
CD8-FITC/cytoplasmic perforin-PE (cytotoxic granule);
and isotype controls (Beckman Coulter). Data was ana-
lyzed using the CXP software (Beckman Coulter).
Statistical Evaluation
The expression of DC markers and the induction of a Treg
or cytotoxic T cell response were evaluated statistically in
3 to 5 replicate cultures by the student's t test or if the data
was not normally distributed the Mann-Whitney Rank
Sum Test using the Sigma Stat analysis program.
Results
CTCL Cells Rendered Apoptotic by CD3 Antibody Binding
MNL including monocytes and CTCL cells obtained from
a leukapheresis harvest of CTCL patients were passed
through an anti-CD3 magnetic bead column to induce
apoptosis in the antigen-experienced CTCL cells and were
then co-cultured with column-passaged monocytes. As a
control, an aliquot of the leukocytes was passed through
an anti-CD4 magnetic bead column, and these viable
CTCL cells were cultured with autologous DC in the same
manner as the apoptotic T cells. In Figure 1, apoptosis was
determined by measurement of the co-expression of the
membrane T cell marker CD3 and cytoplasmic expression
of the early apoptotic marker APO2.7. On primary Day 0
isolation, the percentage of CD3+  cells expressing the
apoptotic marker APO2.7 was 0.646%. After overnight
Induction of CTCL cell apoptosis by anti-CD3 antibody Figure 1
Induction of CTCL cell apoptosis by anti-CD3 anti-
body. CTCL cells were incubated for twenty minutes with 
either anti-CD4 or anti-CD3 antibody and cultured over-
night with column-passaged monocytes. Apoptosis was 
determined on Day 1 by measuring percentage of cells co-
expressing the T cell marker, CD3, and the early apoptotic 
marker, APO2.7. Tx = treated. Statistical analysis performed 
with student's t Test.Journal of Immune Based Therapies and Vaccines 2007, 5:2 http://www.jibtherapies.com/content/5/1/2
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culture, 6.96% of the T cell population bound to anti-CD4
antibody-conjugated beads was apoptotic. When lym-
phocytes were treated with CD3 antibody-conjugated
beads, a 2.96-fold increase (P ≤ 0.001) in the percentage
of apoptotic T cells was found (20.576%). Thus, CTCL
cells treated with anti-CD3 antibody were rendered apop-
totic at a significantly higher percentage and are termed
apoptotic CTCL cells for all future experiments. Those
CTCL cells treated with anti-CD4 antibody had a signifi-
cantly higher percentage of viable cells and are denoted as
viable for the remainder of the experiments.
Passage of Monocytes through Magnetic Column Induces 
DC differentiation
Apoptotic CTCL cells were co-cultured with column-pas-
saged monocytes and markers known to be up regulated
during DC differentiation [12] were analyzed after over-
night culture to determine the ability of passage through
the magnetic bead column to drive the evolution of the
monocyte population into DC. Monocyte differentiation
into immature DC was measured by monitoring changes
in expression of the monocyte marker, CD14, and DC
markers, class II and CD86. Loss of CD14 expression was
revealed by a decrease in the mean fluorescent intensity
(MFI) of the CD14 fluorochrome from primary isolation
on Day 0 followed by co-culture with viable CTCL cells.
The maximum reduction in CD14 MFI was found when
column-passaged monocytes were co-cultured with CTCL
cells rendered apoptotic by CD3 antibody (Fig 2A). A 43%
reduction of expression of the monocyte marker CD14
was found in comparison to the level expressed on mono-
cytes isolated on Day 0 (P ≤ 0.005). There was no signifi-
cant difference in the reduction in CD14 expression
between differentiating DC cultured with viable CTCL
cells or apoptotic CTCL cells. However, the addition of
apoptotic tumor cells enhanced the decrease in CD14
expression while the presence of viable CTCL cells was not
as effective in stabilizing the monocyte to DC conversion.
In addition, expression of class II and CD86 increased sig-
nificantly (P ≤ 0.017–P ≤ 0.029 respectively) upon co-cul-
ture with column-differentiated DC fed apoptotic CTCL
cells as compared to Day 0 controls. Class II expression
increased from the level found on Day 0 monocytes to an
intermediate increase found on the transitioning imma-
ture DC that had been co-cultured with viable CTCL cells
(P ≤ 0.011) to the maximal increase seen when apoptotic
CTCL cells (Fig. 2B) were co-cultured with the immature
DC. A 5.5-fold increase in class II expression was found
when the DC were fed apoptotic CTCL cells and compared
to the monocytes isolated on Day 0. Expression of the co-
stimulatory molecule CD86 also increased from day 0 to
the intermediate increase found on transitioning imma-
ture DC that had been co-cultured with viable CTCL cells
(P ≤ 0.029) to the maximal increase in DC fed apoptotic
DC differentiation from monocytes induced by column pas- sage and apoptotic CTCL cell loading Figure 2
DC differentiation from monocytes induced by col-
umn passage and apoptotic CTCL cell loading. DC 
and apoptotic CTCL cells were co-cultured following passage 
of MNL through an anti-CD3 magnetic bead column. DC dif-
ferentiation was monitored on Day 1 by measuring expres-
sion of cell surface markers using a flow cytometer gated on 
the monocyte population. A. Significant decrease in expres-
sion of monocyte marker CD14 was found on column-pas-
saged monocytes co-cultured with apoptotic CTCL cells 
when compared to the level identified on Day 0 monocytes. 
B. Significant increase in expression of class II was found on 
column-passaged monocytes co-cultured with apoptotic 
CTCL cells when compared to the level identified on Day 0 
monocytes. C. Significant increase in the expression of CD86 
was found on column-passaged monocytes co-cultured with 
apoptotic CTCL cells when compared to the level identified 
on Day 0 monocytes Statistical analysis performed with stu-
dent's t test or Mann Whitney Rank-Sum Test. Apoptotic = 
CD3-treated, Viable = CD4-treated, NS = not significantJournal of Immune Based Therapies and Vaccines 2007, 5:2 http://www.jibtherapies.com/content/5/1/2
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CTCL cells (Fig. 2C). A 25.8-fold increase in CD86 expres-
sion was found when DC that had engulfed apoptotic
cells were compared to monocytes tested on primary iso-
lation. Therefore, passage of CTCL cells through an anti-
CD3 magnetic bead column and subsequent co-culture of
newly apoptotic CTCL cells with column activated mono-
cytes generated significantly enhanced DC differentiation.
Co-culture of column-activated monocytes with viable
CTCL cells was also effective in generating immature DC
but the addition of apoptotic CTCL cells enhanced the
adoption and stabilization of this phenotype.
Induction of a Treg phenotype
Freshly purified CTCL cells were incubated overnight with
DC that had ingested large numbers of apoptotic CTCL
cells using an apoptotic CTCL cell to DC ratio of ≥ 10:1. A
portion of the responding CTCL cell population adopted
the phenotype of T regulatory cells, expressing the cell sur-
face marker CD25 and the cytoplasmic markers CTLA-4
and FoxP3. CTLA-4 was up regulated in the cytoplasm of
CTCL cells exposed to autologous DC that had engulfed
large numbers of apoptotic cells (Fig. 3C), as compared to
the control group (Fig. 3B) and the primary day 0 isolate
Induction of a T regulatory phenotype in CTCL cells Figure 3
Induction of a T regulatory phenotype in CTCL cells. Untreated Day 0 CTCL cells were stained for co-expression of 
CD4 on the cell surface and CTLA-4 in the cytoplasm. DC were fed viable CTCL in ratio of > 10:1 or apoptotic CTCL cells in 
ratios that exceeded 10 viable (B, D, & F) or apoptotic CTCL cells (C, E, & G):1 DC and cultured overnight. Fresh responding 
CTCL cells were added on Day 1 and subsequently co-cultured. On Day 2, co-expression of: B & C membrane CD4 and cyto-
plasmic CTLA4; D & E membrane CD4 and membrane CD25; or F & G cytoplasmic expression of FoxP3 were measured. 
Results are representative of 5 separate experiments performed on cells isolated from cultures of 5 different CTCL patients. 
Apoptotic = CD3-treated, Viable = CD4-treatedJournal of Immune Based Therapies and Vaccines 2007, 5:2 http://www.jibtherapies.com/content/5/1/2
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(Fig 3A). CTCL cell membrane expression of CD25
increased upon co-culture with autologous DC that had
engulfed large numbers of apoptotic CTCL cells (Fig 3E)
as compared to controls (Fig. 3D). The viable CTCL cells
were also partially activated to express increased mem-
brane CD25 (Fig 3D), but not other markers of Treg con-
version (Fig 3B &3F). Cytoplasmic expression of FoxP3
increased 13.9-fold following incubation with autologous
DC that had engulfed large numbers of apoptotic cells
(Fig. 3G) as compared to the control population (Fig. 3F).
Thus, by co-culturing freshly purified CTCL cells with
autologous DC that have engulfed large numbers of apop-
totic CTCL cells, the responding CTCL cells adopt a phe-
notype specific for Treg cells.
We performed a dose response curve by adding increasing
numbers of CTCL cells that had been rendered apoptotic
by incubation with CD3-antibody conjugated to magnetic
beads to overnight cultures of column-generated transi-
tioning DC. We found that in the presence of column-gen-
erated DC that had ingested apoptotic CTCL cells, the
percentage of responding CTCL cells that expressed CTLA-
4 increased as the number of apoptotic cells available for
DC ingestion in the co-culture increased (Fig 4A). A dose
of 0.3 × 106 apoptotic cells fed to 105 DC induced only
4.88% of the freshly added CTCL cells to express cytoplas-
mic CTLA-4. As the dose of apoptotic CTCL cells rose to
1.5 × 106 and 3.0 × 106, the percentage of freshly added
CTCL cells expressing CTLA-4 increased to 12.83% and
18.6% respectively. In contrast, as a control, addition of
increasing numbers of viable CTCL cells to the constant
number of DC did little to enhance the percentage of
CTCL cells expressing CTLA-4. In addition, as the dose of
apoptotic cells fed to a constant number of DC increased,
the percentage of CD4+ T cells expressing FoxP3, the phe-
notypic hallmark of Tregs, increased as well (Fig. 4B). At
0.1 × 106 apoptotic cells fed to a constant number of DC,
the percentage of CTCL cells expressing FoxP3 was 1.45%,
while a 10-fold increase in the apoptotic cell dose to 1.0 ×
106 resulted in a 5.8-fold increase to 8.41% of CD4+ T cells
expressing FoxP3. This dose-dependent increase in FoxP3
expression was not seen in the control group where
increasing numbers of CD4-treated viable CTCL cells were
added to a constant number of DC. Therefore, the gener-
ation of CTLA4+/FoxP3+ Treg cells may be controlled, to
some degree, by the level of apoptotic cells fed to the DC.
Treg CTCL cells suppress CD8-mediated perforin 
expression
As the percentage of CTCL cells that were stimulated to
adopt a Treg phenotype increased, the percentage of CD8+
T cells in co-culture expressing perforin, a granule that
mediates CD8+ effector T cell cytotoxicity [13], inversely
decreased (Fig 5). The percentage of CD3+/CTLA4+ cells
was increased from 4.88% to 18.6% (Fig. 5A) in the pres-
ence of DC loaded with increasing numbers of apoptotic
Dose-response curve of Treg induction in CTCL cells Figure 4
Dose-response curve of Treg induction in CTCL cells. A. Increasing numbers of CD3-treated apoptotic CTCL cells 
(0.3 × 106, 1.5 × 106, 3.0 × 106) were added to a constant number of DC (105), co-cultured overnight and used to stimulate 
freshly isolated autologous CTCL cells. As controls, increasing numbers of non-loaded DC were cultured with CD4-treated 
viable CTCL cells. Then additional CTCL cells were added and co-cultured overnight. The percentage of membrane CD3+/
cytoplasmic CTLA-4+ CTCL cells was measured by flow cytometry gated on the lymphocyte population. B. Increasing numbers 
of apoptotic CTCL cells (0.10 × 106, 0.5 × 106, 1.0 × 106) were added to 105 DC and co-cultured overnight, followed by addi-
tion of 106 purified CTCL cells. The percentage of membrane CD4+/cytoplasmic FoxP3+ expressing cells was measured by flow 
cytometry. Apoptotic = CD3-treated, Viable = CD4-treatedJournal of Immune Based Therapies and Vaccines 2007, 5:2 http://www.jibtherapies.com/content/5/1/2
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cells. Concomitantly, there was a reduction in the percent-
age of cells co-expressing CD8/perforin, from 19.68%
down to 9.87% at the highest dose of apoptotic cells used
to load the DC. Similarly, as the percentage of cells
expressing CD4+/FoxP3+ increased from 1.45% to 8.41%
(driven by a high dose of apoptotic cell DC loading), the
percentage of CD8+ T cells expressing perforin dropped
sharply from 36.69% to 5.58% (Fig. 5B), identifying a
possible threshold of 1–1.5 × 106 apoptotic cells/105 DC
required for induction of a Treg phenotype by the autolo-
gous DC. Therefore, when CTCL cells are induced to adopt
a Treg phenotype by co-culturing them with autologous
DC that have ingested large numbers of apoptotic CTCL
cells, they display the phenotypic characteristics of Treg, a
conversion that may mediate the reduction in the percent-
age of CD8 T cells that express perforin.
Expansion of CD8 T cell compartment following co-
culture with autologous DC that have ingested low 
numbers of apoptotic cells
We next sought to determine whether controlling the level
of apoptotic T cells added to DC could shift the balance of
suppression towards the generation of anti-tumor immu-
nity by loading autologous DC with low numbers of
apoptotic cells. To do this, autologous DC were fed both
a high number of apoptotic CTCL cells (above the demon-
strated level of Treg induction) and a low number of
apoptotic CTCL cells, and expansion of the CD8 T cell
population was monitored. The percentage of CD8 T cells
increased by 83% in the group of DC fed low numbers of
apoptotic T cells (p ≤ 0.042), as compared to control Day
0 samples (Fig. 6A). In addition, the absolute number of
CD8 T cells recovered from overnight culture of column-
passaged DC loaded with apoptotic CTCL cells also
increased by 20% when compared to the initial Day 0
level of CD8 T cells (Fig. 6B). Expansion of the CD8 T cell
compartment was greatest when DC were co-cultured
with a lower number of apoptotic T cells, below the
threshold for Treg induction, and this expanded CD8 T
cell population might hold the potential to generate anti-
tumor immunity.
Increased perforin activity and increased T cell death 
following loading of autologous DC with low numbers of 
apoptotic cells
The expanded CD8 T cell compartment found when
freshly purified CD8+ T cells were co-cultured with autol-
ogous DC that had been loaded with low numbers of
apoptotic cells also demonstrated increased perforin
activity. The percentage of CD8+ T cells expressing per-
forin, the major cytotoxic granule by which effector CD8
cells mediate their anti-tumor effects, rose from 8.4% (Fig
7A) to 13.8% (Fig 7B) when we lowered the dose of apop-
totic cells fed to the DC. This increase in perforin activity
Dose-dependent decrease in CD8-perforin expression as number of phenotypic Treg cells increase Figure 5
Dose-dependent decrease in CD8-perforin expression as number of phenotypic Treg cells increase. A. Increas-
ing numbers of CD3-treated apoptotic CTCL cells (0.3 × 106, 1.5 × 106, 3.0 × 106) were added to a constant number of DC 
(105), co-cultured overnight and used to stimulate freshly isolated autologous CTCL cells and CD8+ cells. As the percentage of 
membrane CD3+/cytoplasmic CTLA4+ cells increased there was an inversely related decrease in the number of membrane 
CD8+/cytoplasmic perforin+ cells. B. Increasing numbers of apoptotic CTCL cells (0.10 × 106, 0.5 × 106, 1.0 × 106) were added 
to 105 DC and co-cultured overnight, followed by addition of 106 purified CTCL cells and CD8+ cells. As the percentage of 
membrane CD4+/cytoplasmic FoxP3+ cells increased, there was an inversely related decrease in the number of membrane 
CD8+/cytoplasmic perforin+ cells. Apoptotic = CD3-treated, Viable = CD4-treatedJournal of Immune Based Therapies and Vaccines 2007, 5:2 http://www.jibtherapies.com/content/5/1/2
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was not seen in the control population, where viable cells
were co-incubated with autologous DC. In addition, the
increased perforin activity translated into significantly
increased T cell death (p ≤ 0.038) in the added CD3+ CTCL
T cell population when CD8 T cells were co-cultured with
low numbers of apoptotic cells and DC (Fig 7E). Under
these conditions, we found that 57% more CTCL cells
were killed in comparison to the level of cell death
obtained when DC were loaded with high numbers of
apoptotic cells and used to prime CD8 T cells. No signifi-
cant change in CTCL cell death was noted when viable
CTCL cells were added to the DC. These results indicate
that the expanded CD8 T cell population not only demon-
strates increased perforin expression phenotypically, but
is also functionally competent to mediate increased apop-
tosis in freshly added CTCL cells.
Discussion
The development of more effective DC-based immuno-
therapy has been hampered by a number of complicating
factors, ranging from the length of culture necessary for
DC development in vitro as well as a lack of knowledge of
the most appropriate stage of DC maturation required for
effective anti-tumor vaccination [14]. In addition, the
most appropriate antigen source for DC loading remains
to be determined, with a variety of existing strategies
including: purified peptides [15]; tumor-targeted viral
vectors [16]; tumor/DC hybrids; apoptotic whole tumor
cells; and tumor lysates having been attempted and
resulted in substantial variability in long-term clinical
responses [17].
Utilizing a magnetic bead column, we were able to gener-
ate potentially immunogenic DC in a fashion that offers
several advantages over existing methodologies: 1) DC
generated in this fashion can be obtained after a single
overnight culture, far more rapidly than existing culture
methods which can take up to 7 days; 2) Apoptotic whole
cells are used as a source of tumor antigen, ensuring that
the spectrum of CTCL antigenicity is incorporated into the
DC instead of singular known antigens which may not be
optimal or may be lost as the tumor de-differentiates; 3)
Passage of monocytes through the column matrix induces
the synchronized differentiation of a large population of
monocytes into DC, allowing for the generation of a more
robust source of APC displaying a spectrum of antigens
upon re-injection; 4) The rapidity and ease of manipulat-
ing the cellular subpopulations of apoptotic CTCL cells
and antigen-presenting cells allows the ability to easily
optimize the cell populations and added factors in the
hope of creating more effective clinical immunotherapy.
In these experiments, we sought to further our under-
standing of the conditions that favor the induction of Treg
cells following exposure to autologous DC co-cultured
with large numbers of apoptotic CTCL cells. The use of the
magnetic bead column provides a new avenue for rapid
generation of tumor-loaded DC because the variety of cel-
Expansion of CD8 T cell compartment following co-culture with DC loaded with low numbers of apoptotic CTCL cells Figure 6
Expansion of CD8 T cell compartment following co-culture with DC loaded with low numbers of apoptotic 
CTCL cells. A. Autologous DC (106) were co-cultured with 1.0 × 106 and 0.25 × 106 apoptotic CTCL cells, followed by addi-
tion of freshly isolated autologous CTCL cells and CD8+ cells. Percentage of CD8+ T cells in co-culture increased significantly 
upon co-culture with autologous DC loaded with 0.25 × 106 apoptotic cells. B. The absolute number of CD8+ T cells increased 
upon co-culture with DC loaded with 0.25 × 106 apoptotic cells. Data analyzed using student's t test. Apoptotic = CD3-
treated, Viable = CD4-treated, NS = Not significant.Journal of Immune Based Therapies and Vaccines 2007, 5:2 http://www.jibtherapies.com/content/5/1/2
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lular components inherent in DC differentiation can be
titrated to optimize dosing with this method.
In our studies, CTCL cells were incubated with anti-CD3
antibody prior to passage through the magnetic bead col-
umn, rendering the antigen-experienced malignant T cells
apoptotic, as had been previously demonstrated. In addi-
tion, the use of anti-CD4 antibody allowed for separation
of CD4+ CTCL cells to be used as a control population
while at the same time not altering the CTCL cells. The
membrane perturbation inherent in monocyte passage
through the column matrix physically stimulates their
transition into DC [18]. DC differentiation was measured
by both the reduction of expression of the monocyte
marker CD14 and the increased expression of class II and
CD86. In all instances, significant changes in the expres-
sion of these cell markers were found, indicating that the
column passaged monocytes were differentiating into DC
and that co-culture of the maturing DC with apoptotic
malignant T cells further stimulated their entry into the
DC pathway. Differentiation of monocytes utilizing
membrane stimulation, as in passage through the column
matrix, is advantageous in particular in the setting of can-
cer immunotherapy since it has been demonstrated that
physical perturbation is one of the more effective means
of cross-priming phagocytosed peptides into the MHC
class I pathway, which is crucial in generation of a CD8
anti-tumor response [18].
Following the generation of potentially immunogenic DC
using the magnetic bead column, we sought to determine
if Treg conversion could be induced. By loading dendritic
cells with large numbers of apoptotic cells, in a ratio of >
10 apoptotic cells to 1 DC, we were able to show that
CTCL cells could be induced to assume some of the phe-
notypic and functional features of Treg cells. These find-
ings correlate with the work of Berger et al, who has shown
that co-culture of freshly purified CTCL cells with autolo-
gous DC loaded with large numbers of apoptotic CTCL
cells can induce a Treg profile in the responding CTCL cell
population, one that has phenotypic and functional char-
acteristics associated with Treg cells [4]. Treg are a subset
of T cells that comprise 5–10% of the peripheral T cell
population, and are involved in the maintenance of
peripheral tolerance and prevention of autoimmune dis-
ease, regulating the response to infectious agents, trans-
planted tissues, and self antigens [19-21]. Treg are
characterized by their ability to suppress immune
responses primarily by inhibiting normal T cell antigen
driven proliferation [22,23]. Treg have been found in
increased numbers in solid tumors and are currently seen
as one of the major hurdles to beneficial clinical responses
in existing immunotherapies [24]. Removal of the sup-
pressive Treg population has been shown to improve the
outcome of cancer immunotherapy in both mouse mod-
els and clinical trials in a number of malignancies [24].
Enhancement of CD8 T cell response upon exposure to  autologous DC loaded with low numbers of apoptotic CTCL  cells Figure 7
Enhancement of CD8 T cell response upon exposure 
to autologous DC loaded with low numbers of apop-
totic CTCL cells. A – D. DC loaded with 1.0 × 106 and 
0.25 × 106 apoptotic malignant T cells stimulated increased 
perforin activity in the CD8 T cell compartment, as com-
pared to DC co-cultured with 1.0 × 106 and 0.25 × 106 viable 
CTCL cells. Results are presented as quadstats measuring 
the expression of membrane CD8/cytoplasmic perforin as 
determined by flow cytometric analysis of the gated lym-
phocyte population. Results are representative of 5 separate 
experiments performed on cells isolated from cultures of 5 
different CTCL patients. E. Increased perforin activity in the 
CD8 T cell compartment translated into increased CTCL cell 
death as measured by membrane CD3/cytoplasmic APO 2.7 
staining. Data analyzed using student's t test. Apoptotic = 
CD3-treated, Viable = CD4-treated, NS = Not significant.Journal of Immune Based Therapies and Vaccines 2007, 5:2 http://www.jibtherapies.com/content/5/1/2
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As the dose of apoptotic CTCL cells fed to a constant
number of DC increased, expression of the Treg-associ-
ated markers CTLA-4, CD25, and FoxP3 also increased
concomitantly. In addition, there appeared to be a thresh-
old ratio of apoptotic cell:DC that corresponded with
induction of the Treg phenotype. As the apoptotic cell:DC
ratio increased from 5:1 to 10:1, expression of the hall-
mark of Treg cells, FoxP3, increased nearly four fold, indi-
cating that perhaps there may be some internal DC
checkpoint related to the number of processed apoptotic
cells that governs the generation of an immune response
versus a suppressive one. While specific mechanisms of
this process remain unclear, we can speculate that perhaps
a CD8 T cell response is favored when low numbers of
peptides are presented while induction of an immunosup-
pressive response requires a higher antigen burden and
presentation of elevated levels of peptides in MHC class II.
In our experiments, the induced phenotypic Tregs also
displayed some functional capabilities, as they were able
to suppress CD8-mediated perforin expression in co-cul-
ture; an observation, which if borne out in vivo, may
explain some of the failures in generating anti-tumor
immunity with existing immunotherapies. These findings
are in concert with our previous studies which demon-
strated that cultured CTCL cells can be stimulated to
assume a Treg phenotype and function suppressing nor-
mal T cell driven immune responses when exposed to DC
that have ingested apoptotic cells [4]. In our present stud-
ies, we demonstrate that, in addition, freshly isolated
CTCL cells can be driven to adopt a Treg phenotype by
overnight exposure to DC loaded with large numbers of
apoptotic cells.
By establishing that Treg cells could be rapidly generated
using this method, we then sought to determine if that
delicate balance between the DC and surrounding num-
bers of apoptotic cells could be shifted in the other direc-
tion, towards stimulating a more vigorous immune
response. By lowering the dose of apoptotic cells proc-
essed by a constant number of DC, we were able to induce
significant expansion of the CD8 T cell compartment. This
expanded CD8 T cell compartment not only contained a
greater percentage of perforin expressing cells but also
mediated increased T cell death in the added CTCL cell
population. In terms of existing immunotherapies, these
findings hold major clues into possible mechanisms for
tumor survival following treatment. If too aggressive an
attempt is made at killing tumor cells in hopes of loading
DC with large number of tumor antigens, it may lead to
Treg generation and suppression of the desired immune
response. A considerable body of literature exists support-
ing the idea that the difference between the DC's ability to
induce tolerance or mediate immunity may be deter-
mined by its persistent exposure to antigen. [25,26] In our
experiments, the DC that were exposed to larger numbers
of apoptotic cells and hence had more persistent antigen
exposure induced suppression of the CD8 T cell popula-
tion. These findings support earlier work and help to rein-
force the role of apoptosis in the induction of
immunosuppression. [27,28]
A better understanding of the role of Treg cells in immu-
notherapy is crucial because while they hamper the effec-
tiveness of cancer immunotherapy [24], Treg may be of
great value for the therapy of autoimmune disease and
transplantation tolerance. [21,29] The ability to use rapid
methods such as the magnetic bead column allows for
optimization of existing methodologies so that we can
improve our understanding of apoptotic T cell and DC
interactions, with the goal of creating more effective can-
cer immunotherapy.
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